pharma · Inflammatory Bowel Disease (IBD) · Melanoma · IRON
Disc Medicine
Disc Medicine is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker IRON. Primary therapeutic focus areas include Inflammatory Bowel Disease (IBD), Melanoma, Parkinson's disease, Falcip
321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US HQ
165 Employees
Public company Type
IRON · NYSE Ticker
Company details
- Status
- Public
- HQ
- 321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US
- Employees
- 165
- Programs
- 308
- Drugs
- 443
- Patents
- 706
Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors
Phase 1 · other · locally advanced or metastatic, well-differentiated gastro-enteropancreatic neuroendocrine tumors.
Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors for locally advanced or metastatic, well-differentiated gastro-enteropancreatic neuroendocrine tumors. is a Phase 1 program (other) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Internal code NL79259.078.21
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Disc Medicine
- Phase
- Phase 1
- Modality
- other
- Indication
- locally advanced or metastatic, well-differentiated gastro-enteropancreatic neuroendocrine tumors.
- Status
- active
- Trials
- 1